Replimune Group (NASDAQ:REPL) Shares Up 9.6% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL) shares rose 9.6% during trading on Monday . The stock traded as high as $10.94 and last traded at $11.1710. 740,133 shares traded hands during trading, a decline of 84% from the average session volume of 4,696,079 shares. The stock had previously closed at $10.19.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on REPL shares. Wedbush raised their price target on shares of Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a report on Monday, June 1st. BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research report on Monday, April 13th. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Finally, Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research note on Friday, April 10th. Seven analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $4.88.

Replimune Group Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The stock’s 50 day moving average price is $5.43 and its two-hundred day moving average price is $7.25. The firm has a market capitalization of $915.29 million, a price-to-earnings ratio of -3.24 and a beta of 0.88.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. The trade was a 6.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in the business. RTW Investments LP lifted its position in shares of Replimune Group by 11.6% during the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock worth $69,404,000 after purchasing an additional 744,620 shares during the last quarter. Fcpm Iii Services B.V. grew its holdings in Replimune Group by 6.4% in the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after buying an additional 248,672 shares during the last quarter. State Street Corp increased its position in Replimune Group by 26.3% in the 4th quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after buying an additional 768,982 shares during the period. Vanguard Group Inc. increased its position in Replimune Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after buying an additional 9,707 shares during the period. Finally, Braidwell LP lifted its holdings in shares of Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after buying an additional 2,327,205 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.